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Abstract
Background: Preoperative evaluation of ovarian tumors is challenging. This study was undertaken to evaluate the
performance of conventional two-dimensional (2D) ultrasound and CA125 in predicting malignant or benign nature
of pelvic masses, and to investigate if three-dimensional power Doppler (3DPD) ultrasound provides any added
value. Ninety-six postmenopausal and four perimenopausal women with supposed ovarian tumors were examined
by standardized 2D and 3DPD ultrasounds preoperatively. The tumors were evaluated using the risk of malignancy
index (RMI), International Ovarian Tumors Analysis (IOTA) group simple rules, expert opinion, IOTA logistic regression
model 2 (LR2) and 3D vascular indices, and were postoperatively compared to histopathological results.
Results: Ninety-eight tumors turned out to be ovarian in origin. Of these, 66 were benign and 32 malignant. RMI
(cut-off value 200), simple rules, expert opinion and LR2 (cut-off value 25) were used to predict malignant nature of
the tumors and had sensitivities of 71.9, 90.6, 87.5 and 90.6%, and specificities of 80.3, 84.6, 92.4 and 77.3%, respectively.
When the 3D vascularization flow index (VFI) was added to RMI and LR2, the accuracy of the test improved from 77.6
to 81.4% and from 81.6 to 86.5%, respectively, at the expense of sensitivity, while VFI gave no added benefit for simple
rules and expert opinion. Agreement between two examiners using expert opinion was good (Cohen’s kappa = 0.89).
Conclusions: The subjective opinion of an expert seems to be the most reliable method in assessing ovarian tumors,
and the 3DPD indices seem to provide no significant added value.
Keywords: Expert opinion, IOTA LR2, IOTA simple rules, Ovarian cancer, Ovarian tumor, Power doppler, Three-
dimensional ultrasound
Background
Ovarian cancer has the leading mortality rate of all
gynecological cancers, and the incidence of ovarian can-
cer is at its peak among postmenopausal women. The
optimal treatment of ovarian neoplasms requires correct
preoperative characterization of tumors. The surgical
treatment of ovarian cancer should be reserved for
gynecological oncologists, while benign tumors can be
operated on less radically by general gynecologists, or
even managed conservatively.
Preoperatively ultrasound features combined with the
measurements of CA125 has been used to predict the
malignancy of a pelvis mass (Risk of Malignancy Index,
RMI) since early 1990’s [1]. However, subjective assess-
ment by an experienced ultrasound examiner has been
considered to be the best diagnostic method for ovarian
tumors [2, 3]. While not all gynecologists are so well ac-
customed to ultrasound examinations, in 2008 the Inter-
national Ovarian Tumors Analysis (IOTA) group
presented simple ultrasound-based rules that include
five rules for predicting malignant tumors (M-rules) and
five for predicting benign tumors (B-rules). If one or
more M-rules with absence of B-rules or B-rules with
absence of M-rules are present, the tumor is supposed
to be malignant or benign, respectively. In a multicenter
study, these rules were applicable for 76% of all tumors
and showed a sensitivity of 95% and specificity of 91%
[4]. If none of the rules is valid or if both M- and B-rules
are present, a tumor is considered to be inconclusive
[4, 5]. In that case the opinion of an expert ultra-
sound examiner is needed, which is called a two-step
strategy [6]. In addition, the IOTA group developed
two logistic regression models (LR1 and LR2) [7].
LR1 is based on 12 different variables, and LR2 is
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based on 6, including patient history, clinical signs
and ultrasound features. These models have shown
sensitivities of 92–95% and 89–95% with specificities
of 74–87% and 73–86% in detecting ovarian malig-
nancies, respectively [8]. Nevertheless, in several stud-
ies, the impression of an expert ultrasound examiner
has still been considered to be the best method, or at
least equivalent to LR1 and LR2, for diagnosing ovar-
ian pathology [8, 9].
An increased density of microvessels and abnormal
vascular tree of the tumor are characteristic of malignant
ovarian processes [10, 11]. These phenomena have given
new insight for the use of three-dimensional (3D) ultra-
sound and 3D power Doppler (3DPD) in evaluating the
vascularization of ovarian tumors to discriminate be-
tween benign and malignant tumors. Unfortunately,
there are no clear cut-off rules for 3D ultrasound fea-
tures, limiting their clinical utility [12].
The purpose of this study was to examine if 3DPD
ultrasound can offer additional benefits over conven-
tional two-dimensional ultrasound and other diagnostic
methods as a useful tool for predicting malignancy of an
adnexal mass. The aim was to find the most applicable
and reliable preoperative diagnostic approach for post-
menopausal women.
Methods
Between February 2011 and November 2014, one hun-
dred women over 50 years of age presenting with an ab-
normal adnexal mass(es) at the Department of
Obstetrics and Gynecology of Tampere University Hos-
pital, were recruited to the study. All patients were des-
tined for surgery. Overtly benign or malignant looking
tumors like unilocular simple ovarian cysts and tumors
associated with marked ascites (depth of the greatest
pool over 10 cm) were excluded. In principle, the max-
imum allowed diameter of the tumors was 10 cm, allow-
ing the entire tumor to be assessible transvaginally.
However, there were five tumors, the maximum diam-
eter of which exceeded 10 cm at the final examination,
but it never exceeded 12 cm.
According to preoperative findings, the patients were
operated on by either a gynecological oncologist or a
general gynecologist, using either laparoscopic or open
technique.
The patients were assessed within 2 weeks prior to
surgery by vaginal two-dimensional (2D) and 3D ultra-
sound examination with power Doppler. In the case of
bilateral ovarian tumors, both masses were examined,
and the more complex tumor was assessed for the study.
All ultrasound examinations were performed by an
experienced gynecologist or the author R.J.N., using a
Voluson 730 Expert unit (GE Medical Systems, Zipf,
Austria) with a multifrequency transvaginal transducer
(5–9 MHz). A normal B-mode ultrasound assessment
included the calculation of the size of the adnexal mass.
The power Doppler settings were standardized: fre-
quency, 6 MHz; power Doppler gain, -0.6; wall motion
filter (WMF), low 1; pulse repetition filter (PRF),
0.6 kHz. The extent of vascularization of the tumor was
described by a score from 1 to 4 (1 = no blood flow de-
tected, 4 = high blood flow detected) [13]. 3DPD was
used to examine the ovarian tumor after the 2D evalu-
ation. The acquisition sweep angle was set to 85°.
A serum sample was obtained preoperatively, and RMI
was calculated by using the original formula of Jacobs et
al. in which the serum CA125 level, ultrasound scan re-
sult and patient’s menopausal status are taken into ac-
count [1]. The ultrasound data were stored on a hard
disk for later evaluation. Based on the ultrasound exam-
ination, the examiner classified the adnexal tumor as be-
nign or malignant (expert opinion), immediately
following the actual examination. From the 2D data, the
tumors were classified by using the IOTA simple rules.
If none of these rules applied or if both M- and B-rules
were applicable, the tumor could not be classified. In
such case, the tumor was evaluated subjectively by the
examiner as benign or malignant.
The IOTA LR2 was implemented by using the Predict-
ive IOTA models for ovarian cancer application soft-
ware, version 2013 (App for IOS operating systems). In
the LR2 model, the six variables used are age of the pa-
tient, presence/absence of ascites, presence/absence of
papillations/papillary projections with blood flow, max-
imum diameter of the largest solid component, irregular
cyst walls and presence/absence of acoustic shadows.
This calculated model yields the probability of malig-
nancy of an ovarian tumor.
The analyses of the stored 3D volumes were per-
formed by the same investigator (R.J.N.) using a virtual
organ computer-aided analysis (VOCAL™) imaging pro-
gram and 4D-View software (GE Healthcare, v 9.1). The
volume of each adnexal tumor was measured by manual
delineation of the contour of the mass with a 15°-rota-
tion step. Using the VOCAL software’s histogram fea-
ture, three vascular indices were calculated from the
adnexal tumors: vascularization index (VI), flow index
(FI) and vascularization flow index (VFI). VI represents
the number of vessels in the studied volume and is
expressed as a percentage. FI reflects the intensity of
blood flow at the time of the 3D sweep. VFI is inter-
preted to be a combination of VI and FI representing
both vascularization and blood flow. FI and VFI are
expressed as values ranging from 0 to 100 [12, 14, 15].
To estimate the interobserver agreement, another ex-
perienced ultrasound examiner (S.K.S.) re-evaluated the
stored ultrasound data and classified the malignancy of
tumors (expert opinion), and analysed 3D volumes.
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The ultrasound examinations and off-line assessments
were performed blinded for each other’s results and the
histopathological diagnoses while analyzing the tumors.
The preoperative findings were finally compared to post-
operative histopathological diagnoses. For the purpose of
this analysis, the borderline and low grade ovarian tu-
mors were classified as malignant because normally also
they are staged surgically. All participants gave their in-
formed consent to the study, which was approved by the
Ethics Committee of Tampere University Hospital (ETL
R10080, 6 August 2010).
Statistical analysis
No sample size calculation was performed due to the
preliminary descriptive nature of this study. All data
were analyzed using IBM SPSS Statistics for Windows,
version 22 (Armonk, NY, IBM Corp.). The normality of
the distributions of continuous variables was evaluated
by Kolmogorov-Smirnov tests. Due to the skewness of
the distributions, the comparisons of groups were per-
formed using Mann-Whitney U-tests, and correlations
were evaluated using Spearman’s correlation tests. Re-
ceiver operating characteristics curves (ROC) were used
for evaluating the performance of serum CA125, RMI,
LR2 and 3D vascular indices as predictive tests for
malignancy. The best cut-off values of the models were
calculated in consideration of sensitivity, specificity,
positive predictive value and negative predictive value.
Binomial variables were evaluated by Fischer’s exact tests
or Pearson Chi-Square tests when appropriate.
The agreement of ultrasound features by both ultra-
sound examiners (R.J.N. and S.K.S.) was estimated by cal-
culating the Cohen’s kappa index. A kappa value of less
than 0.20 indicates poor agreement, 0.21–0.40 moderate
agreement, 0.61–0.80 good agreement and 0.81–1.00 very
good agreement [16]. Interobserver agreement of 3DPD
indices were analyzed by related-samples Wilcoxon signed
rank test.
Results
In 100 patients with supposed adnexal masses, the
tumors of 98 patients turned out to be true ovarian
tumors, while the remaining two were appendiceal in
origin. Of the 98 ovarian tumors, sixty-six (67.3%) were
benign, of which 19 were bilateral. Respectively, 32
(32.7%) of the tumors were malignant, of which six were
bilateral. Of the malignant tumors, 17 were epithelial
serous, five epithelial mucinous, and eight of other path-
ology. Two of the malignant tumors were metastases of
intestinal cancer. The histologic diagnoses of adnexal
masses are presented in Table 1.
The median age of the patients was 61 (range, 50–84)
years. Tumor pathology did not depend on the age of
the women or the bilaterality of the tumors. Three of
the women in the benign ovarian tumor group and one
in the malignant group were in fact perimenopausal, be-
cause they had experienced menstrual bleeding during
the previous 6 months. Systemic hormone replacement
therapy was used before surgery by 17 women with be-
nign tumors and by five with malignant tumors. The
median body mass index was 26 (range, 20–44) for
women with benign tumors and respectively 27 (range,
19–39) for women with malignant tumors. The median
diameters of the tumors in the groups were 6 (range,
3–11) and 7 (range, 3–12) cm, respectively. The me-
dian serum CA125 levels were 15 (range, 6–127) and
50 (range, 9–3195) kU/L, respectively, and the differ-
ence between the groups was significant (p < 0.001).
The calculated median values of RMI for benign and
malignant cases were 99 (range, 10–1143) and 360
(range, 27–7488), respectively (p < 0.001). The age of
the patients, body mass indexes and CA125 levels did
not correlate with each other.
The performances of the assessed methods are given
in Table 2. Seventy-six (77.6%) of the tumors were
Table 1 Histology of the tumors
Histologic type Number Percent
Benign 66 (67.3)
Serous cystadenoma/adenofibroma 39
Fibroma/thecoma 5
Teratoma 7
Brenner tumor 1
Endometrioma 3
Mucinous cystadenoma 3
Serous/hemorrhagic cyst 7
Bizarre leiomyoma 1
Malignant 32 (32.7)
Epithelial tumors
Serous
High grade 9
Low grade 3
Borderline 5
Mucinous
Adenocarcinoma 3
Borderline 2
Clear cell carcinoma 1
Carcinosarcoma 2
Non-epithelial tumors
Granulosa cell tumor 4
Sertoli-Leydig cell tumor 1
Metastatica 2
Total 98 (100.0)
aPrimary tumors: sigmoid carcinoma and carcinoma of the appendix
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classifiable using the simple rules, and 68 of these
(89.5%) were correctly classified. Incorrectly classified
tumors were all false-positive malignant tumors, and
their histopathological diagnoses were serous cystade-
noma/-fibroma (n = 4), thecoma (n = 2), one serous cyst
and one Brenner tumor each. The unclassifiable tumors
(n = 22) were evaluated by expert opinion (R.J.N.), and
77.3% (17 of 22) were classified correctly.
The opinions of the experts (R.J.N. and S.K.S.) differed
in five cases, including two serous and one mucinous
cystadenoma, one teratoma, and one benign Brenner
tumor. In addition, both experts failed in the case of two
malignant tumors: one endometrioid adenocarcinoma
FIGO Stage IA and one granulosa cell tumor. Two ser-
ous borderline cystadenomas were erroneously classified
as benign. The interobserver agreement of the malig-
nancy of tumors between both examiners was very good
(Cohen’s kappa = 0.89, 95% CI 0.79–0.98; percentage of
agreement of correct classification = 87.8%).
The tumor vascularity as examined by 2D ultrasound
was higher in malignant tumors compared to benign tu-
mors (p < 0.001). Predictions of tumor malignancy by
scoring the vascularity yielded the same sensitivity
(90.6%) as the simple rules with the expert opinion and
LR2 with a cut-off value of 25. In comparison, 81.6% (80
of 98) of the tumors were classified correctly by vascu-
larity assessment and LR2 (with a cut-off value 25),
whereas the expert opinion correctly diagnosed 90.8%
(89 of 98) of the cases. LR2 values and 3D vascular indi-
ces (VI, FI and VFI) were significantly different between
benign and malignant tumors (p < 0.001). VI and VFI
were the most sensitive and specific 3DPD indices
(Table 3), being at least as specific as RMI, simple rules
and LR2 in detecting malignant tumors. The subjective
evaluation of tumor vascularity by 2DPD was more sen-
sitive and almost as specific and accurate as 3DPD vas-
cular indices. When 2D vascularity scoring or LR2 was
combined to simple rules with the expert opinion, the
Table 2 Diagnostic performances of different methods at various cut-off values in detecting ovarian malignancy
Diagnostic method
Cut-off value
Sensitivity
%
95% CI Specificity
%
95% CI PPV
%
95% CI NPV
%
95% CI Accuracy
%
Serum CA125 (kU/L)→ Area under the ROC curve = 0.80
24 71.9 53.3–86.3 78.8 67.0–87.9 62.2 44.8–77.5 85.3 73.8–93.0 76.5
35 59.4 40.6–76.3 84.9 73.9–92.5 65.5 45.7–82.1 81.2 69.9–89.6 76.5
RMI→ Area under the ROC curve = 0.81
200 71.9 53.3–86.3 80.3 68.7–89.1 63.9 46.2–79.2 85.5 74.2–93.1 77.6
220 71.9 53.3–86.3 83.3 72.1–91.4 67.7 49.5–82.6 85.9 75.0–93.4 79.6
Simple rules with expert opiniona 90.6 75.0–98.0 84.6 73.9–92.5 74.4 57.9–87.0 94.9 85.9–98.9 86.7
Expert opinion 87.5 71.0–96.5 92.4 83.2–97.5 84.6 68.1–94.9 93.9 85.0–98.3 90.8
Tumor vascularityb 90.6 75.0–98.0 77.3 65.3–86.7 65.9 50.1–79.5 94.4 84.6–98.8 81.6
LR2 (%)→ Area under the ROC curve = 0.93
10 100.0 89.1–100.0 36.4 24.9–49.1 43.2 31.8–55.3 100.0 85.8–100.0 57.1
25 90.6 75.0–98.0 77.3 65.3–86.7 65.9 50.1–79.5 94.4 84.6–98.8 81.6
43 81.3 63.6–92.8 90.9 81.3–96.6 81.3 63.6–92.8 90.9 81.3–96.6 87.8
IOTA International Ovarian Tumor Analysis; CI Confidential interval; PPV Positive predictive value; NPV Negative predictive value; ROC Receiver operating
characteristics; RMI Risk of malignancy index; LR2 Logistic regression model 2
aTwo-step strategy: as a result of inconclusive findings by simple rules, the expert evaluates the tumor
bTwo-dimensional ultrasound vascular score 1-2 vs 3-4
Table 3 Diagnostic performances of three-dimensional power Doppler indices at different cut-off values in detecting ovarian malignancy
3DPD indices
Cut-off value
Sensitivity
%
95%
CI
Specificity
%
95%
CI
PPV
%
95%
CI
NPV
%
95%
CI
Accuracy
%
VI (%)→ Area under the ROC curve = 0.86
1.00 67.7 48.6–83.3 90.9 81.3–96.6 77.8 57.7–91.4 85.7 75.3–92.9 83.5
FI→ Area under the ROC curve = 0.72
30 83.9 66.3–94.6 51.5 38.9–64.0 44.8 31.7–58.5 87.2 72.6–95.7 61.9
VFI→ Area under the ROC curve = 0.87
0.31 71.0 52.0–85.8 89.4 79.4–95.6 75.9 56.5–89.7 86.8 76.4–93.8 83.5
3DPD Three-dimensional power Doppler; CI Confidential interval; PPV Positive predictive value; NPV Negative predictive value; ROC Receiver operating characteristics; VI
Vascularization index; FI Flow index; VFI Vascularization flow index
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specificity slightly increased, albeit at the expense of
sensitivity (data not shown).
The interobserver agreement between the two experts
was good also in the case of calculated 3DPD indices, as
shown in Table 4.
By combining RMI and LR2 with VFI and using suit-
able cut-off values, the accuracies and specificities of
RMI and LR2 improved, while their sensitivities de-
creased. On the other hand, combining these 3DPD
indices with simple rules or the expert opinion did not
improve either method’s accuracy. Newly created com-
bination models are given in Table 5.
Discussion
To the best of our knowledge, this is the first study to
compare such a large spectrum of various preoperative
methods (serum CA125, RMI, simple ultrasound rules,
expert opinion, 2DPD and IOTA LR2) along with 3DPD
indices for discrimination between benign and malignant
ovarian tumors. The results of the present study imply
that clinical expert opinion still provides the best
method for diagnosing malignant ovarian tumors, with
no additional benefit provided by use of 3DPD indices.
Regarding the specificity of 3DPD indices, VI and VFI
are only as specific as the traditional methods CA125
and RMI, but the combination of them with LR2 and
RMI provides a clear improvement of specificity, but
unfortunately at the expense of sensitivity.
The present results regarding the superiority of ex-
pert opinion are in accordance with previous studies.
Timmerman et al. [5] found in their prospective study
comparing IOTA-based simple rules, LR1 and LR2,
and subjective assessment of the sonologist that ex-
pert’s opinion is either better or equivalent to the
scoring systems.
A weakness of this study is the rather small number of
patients, but on the other hand, all the patients were ex-
amined by the same investigator, which in turn can be
considered to be an advantage. Moreover, the data was
assessed by another examiner yielding a very good agree-
ment between both examiners. Another advantage is a
quite homogenous patient population, with only four
perimenopausal women among 96 postmenopausal pa-
tients. A potential bias of the study is that although RMI
was originally developed as a triage test for use by a less
experienced ultrasound examiner to predict the malig-
nancy of a tumor, in this study it was rather used by an
ultrasound expert in parallel with simple rules and LR2
designed to triage patients who should be operated on
by a gynecologic oncologist [5, 8]. The main rationale
for including also RMI was to provide a reader less expe-
rienced in ultrasound, with a familiar comparator for the
more specific triage methods.
CA125 is widely used as a tumor marker for epithelial
ovarian cancer. It is quite accurate among postmeno-
pausal women, while the relatively great number of
false-positive results limits its utility in premenopausal
setting. Our cut-off value was 35 kU/L, whereas some
reports have used lower cut-offs, which might explain
the lower sensitivity of CA125 (59.4%) in our study. In a
review article on seven studies, the pooled sensitivity
and specificity of CA125 in postmenopausal women
were 85.9 and 85.2%, respectively [17]. We also tested a
lower cut-off value of 24 kU/L, which clearly improved
sensitivity, while somewhat weakening specificity.
In their original study, Jacobs et al. described a sensi-
tivity of 85% and a specificity of 97% for a RMI cut-off
level of 200 [1]. A review of RMI on 13 studies showed
that for a cut-off level of 200, the pooled estimate for
sensitivity was 78% (95% CI 71–85%) and for specificity
was 87% (95% CI 83–91%), which is still better than in
our study [18]. The reason for this may be our rather
limited sample size, or the fact that the majority of the
malignant tumors were of low malignant potential i.e.
borderline epithelial, granulosa and Sertoli-Leydig cell
tumors, which may have contributed to the less-than-
optimal performance of RMI.
An IOTA-based protocol classified a woman as being
at high risk for ovarian malignancy if the estimated LR2
risk was at least 25%, at intermediate risk if LR2 was be-
tween 5 and 25% and at low risk if LR2 was below 5%
[19]. It has been presumed that the LR2-based protocol
is more accurate than the RMI-based protocol, and is
recommended to be used instead of RMI in discriminat-
ing ovarian tumors and concluding treatment protocols
[19]. In the multicenter study of Testa et al., LR2 and
RMI achieved AUC values of 0.90 and 0.85, respectively
in 1,049 postmenopausal patients [6]. The corresponding
AUC values in the present study were quite similar, 0.93
and 0.81. We argue that LR2 ≥ 25% risk is the most prac-
tical value in clinical work because in our study it
achieved a negative predictive value of 94.4%.
Different preoperative scoring systems of ovarian tu-
mors were evaluated in the meta-analysis of Kaijser et al.
The pooled sensitivity and specificity of simple rules in
five validated studies were found to be 93 and 81%,
Table 4 Interobserver agreement between two experts using
three-dimensional power Doppler (3DPD) indices
3DPD
indices
Expert opinion 1 Expert opinion 2 p-valuea
Median
(25–75% quartiles)
Median
(25–75% quartiles)
VI 0.337 (0.069–1.098) 0.259 (0.066–0.894) 0.151
FI 31.796 (25.308–35.821) 31.693 (26.351–36.638) 0.839
VFI 0.112 (0.019–0.397) 0.079 (0.019–0.292) 0.257
3DPD Three-dimensional power Doppler; VI Vascularization index; FI Flow
index; VFI Vascularization flow index
aCalculated by related-samples Wilcoxon signed rank test
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respectively [20]. However, the inconclusive cases were
assessed to be malignant, which differs from our study
where in the inconclusive results obtained by the simple
rules protocol, the tumors were subjectively classified as
being either benign or malignant by the same examiner.
This is described as a two-step strategy [6]. In our data
85/98 of tumors were classified correctly by using this
two-step strategy. Only three of 13 incorrectly classified
tumors were false negative, or they were malignant al-
though they were classified as benign. We reached
equivalent results as the meta-analysis by Testa et al.,
which yielded a sensitivity of 93% and specificity of 83%
for the two-step strategy in postmenopausal women [6].
Our results are also in line with a large database of
IOTA studies which has shown that the pattern recogni-
tion by an experienced clinician is the best method in
assessing ovarian tumors [8]. Recently, Piovano et al.
showed that when serum CA125 was added to simple
rules with subjective assessment for diagnosing ovarian
tumors, the diagnostic accuracy increased, with an ac-
ceptable cost/benefit ratio [21].
In recent years, several studies have been published,
where 3D ultrasound assessment has been used in
gynecological cancers, including ovarian cancer. It has
been shown that 3DPD vascular indices are elevated in
malignant ovarian tumors [22]. Jokubkiene et al. also
found this difference, but quantitative 3DPD indices of
an ovarian tumor measured by another expert did not
add any significant information to subjective quantita-
tion by the original examiner of 2DPD findings [23].
Similarly, Guerriero et al. reported that 3DPD indices
failed to improve accuracy as a secondary test for ovar-
ian tumors alongside the evaluation of central
vascularization by 2DPD [24]. On the contrary, Geomini
et al. found that 3D ultrasonography significantly im-
proved the discrimination of ovarian pathology, when
they compared 2D to 3D ultrasound models [25]. Two
methods of vascular sampling, manual [22] and spherical
[23], have been purported to be alternatives to measur-
ing the vascularity of the whole tumor, but based on our
experience, the entire tumor should be taken account. In
support of this, Kudla and Alcazar have shown that the
size of the sphere volume does not affect power Doppler
indices [26].
Our results do not differ from those of the only previ-
ous study that compared simple rules and 3DPD. The
study of Silvestre et al. assessed 3DPD examination and
simple rules in the identification of ovarian tumors [27].
They did not use other preoperative diagnostic methods,
and the menopausal status of the patients was ignored.
Similar to our study, the ovarian tumors were classified
by conventional 2DPD according to IOTA vascular
scores. They found that VI and VFI differentiated malig-
nant tumors from benign ones, but they were not more
accurate than 2D vascular scores. The use of 3D vascular
indices did not decrease the number of false positive
results obtained by simple rules.
Conclusions
Combining the 3DPD vascular index VFI with RMI or
LR2 may increase the specificity of the diagnostic test, but
an ultrasound examination by an experienced clinician still
seems to be the most reliable method in the preoperative
work-up of ovarian tumors.
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